LA JOLLA, Calif., July 13 /PRNewswire/ -- La Jolla Diagnostics, Inc. (OTC Bulletin Board: LAJD) announced today that an article on the company has just appeared in the Sun Country Airlines Magazine.
This article in the magazine, which will be exposed to 2,000,000 enplanements, is titled: LA JOLLA DIAGNOSTICS: Heading for Big Things in Migraine Treatment? It discusses the company, the patented ClusterWater technology used in its nutriceutic products including a product for the possible treatment of migraine headaches.
This article follows on the heels of an announcement last week by La Jolla Diagnostics which disclosed the conclusion of a European distribution agreement along with a $200,000 initial purchase order.
The La Jolla Diagnostics products to be distributed include:
* Feverfew Nasal Mist(TM), a patent pending moisturizing nasal spray,
* MigraSpray(TM) a saline solution containing the herb feverfew (commonly used as a treatment for migraine headaches) and designed to be sprayed under the tongue,
* Living Water Eye Lotion(TM), a saline solution which cleanses and soothes the eye without interfering with natural functions, and
* OptoPet(TM) Eye Wash for cleansing the eyes of dogs and cats and removing mucous which causes fur stains beneath the eyes, a major problem in certain breeds.
These products are prepared using water processed by a recently patented technology* to form ClusterWater(TM). While remaining chemically identical with unprocessed water, ClusterWater forms polywater complexes which enhance the effectiveness of biological solutions.
*U.S. Patent 5711950
Distribution of La Jolla's feverfew products has recently been made more efficient by a process which enhances heat stability.
La Jolla Diagnostics is a company engaged in the development and marketing of diagnostic tests and consumer health care products, and the licensing of drug delivery systems.
SOURCE La Jolla Diagnostics, Inc.
/CONTACT: La Jolla Diagnostics, Inc., 800-454-6790, or Fax: 619-454-7851/
/Web site: lajd.com
(LAJD)
|
